ClinicalTrials.gg
RecruitingNCT07266389Updated Nov 17, 2026

Clinical Efficacy Evaluation of Supraglottic Airway Device SafeLM™ in Paediatric Population

An interventional study of SafeLM™ as the airway management device during general anaesthesia in Anesthesia, Supraglottic Airway Efficiency and Paediatric Airway Management, sponsored by National University of Malaysia. Recruiting at 2 sites in Malaysia. Open to participants aged 0 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National University of Malaysia · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
0 Years to 18 Years
Sex
All
01

Study summary

The goal of this interventional study is to evaluate the clinical efficacy of SafeLM™, a video laryngeal mask airway device in paediatric population. The main questions it aims to answer are:

  1. To determine the success rate, ease of device insertion, time for insertion, and how well the device seals the airway by measuring the oropharyngeal leak pressure (OPLP) of SafeLM™.
  2. To determine the incidence of complication associated with SafeLM™ usage.
  3. To study the association of glottic view with success rate and rate of complication.

Participants perioperative clinical data will be collected for data analysis.

Read the detailed description

Paediatric patients who are scheduled for surgery where supraglottic airway is deemed appropriate will be recruited with written consent. Following preoxygenation, application of standard monitors, and induction of general anaesthesia, an appropriate size of SafeLM™ will be inserted according to manufacturer's recommendation. Cuff will be deflated and flattened prior, with the back of laryngeal mask lubricated. The device will be advanced by sliding the laryngeal mask down the palatopharyngeal curve along the midline in the mouth until the end of the mask reach the hypopharynx cavity and resistance is met, with the process visualised in real time through the video camera. If there is malalignment, correction manoeuvre such as jaw trust, head reposition, or mask redirection will be done. Once the distal end of mask reaches the hypopharyngeal cavity, the cuff is inflated with the recommended volume of air according to the manufacturer recommendation, until adequate cuff seal is achieved. Then, the patient is put on either spontaneous or pressure-controlled mechanical ventilation. Successful placement will be confirmed. If insertion difficulty is encountered and the laryngeal mask is required to be taken out from the oral cavity, insertion can be reattempt with the same or different size of SafeLM™ after adequate preoxygenation, and it will be considered as second attempt. If it remains unsuccessful on the 3rd attempt, SafeLM™ insertion will be abandoned, subsequent management will be decided by the attending anaesthetist. Glottic exposure grades at the end of each attempt is recorded. The time for insertion is measured for each attempt, using a stopwatch, by obtaining the duration in between the moment when the anaesthetist starts holding the SafeLM™ device, until the appearance of 2 complete continuous capnography waveform on the monitor. Following successful SafeLM™ insertion, the camera can be removed, and orogastric tube will be inserted via the gastric port only if there is clinical indication. Subsequently, oropharyngeal leak pressure (OPLP) is measured and recorded by dialing the fresh gas flow rate to 3 L/min and putting the adjusting pressure limiting (APL) valve at 40 cmH2O, in manual ventilation mode. The equilibrium pressure that the pressure gauze pointer settles down at is the OPLP. The anaesthesia is maintained using TIVA or volatile agent as per the anaesthetist's discretion, keeping the MAC at least 1.0 or BIS level at 40-60, whichever is applicable. All the patients will receive IV dexamethasone 0.2 mg/kg and IV granisetron 0.02 mg/kg as post operative nausea vomiting (PONV) prophylaxis. At the end of anaesthesia, anaesthetic agent administration is terminated. If non-depolarising neuromuscular blockade is given during anaesthesia, an appropriate dose of reversal agent will be given according to the depth of neuromuscular blockade based on either clinical signs or nerve stimulation examination, whichever applicable. After the adequate neuromuscular blockade reversal is confirmed, the laryngeal mask can be removed at the awake state or deep plane of anaesthesia. Patient will be monitored in the post-anaesthesia care unit for at least 30 minutes prior sending back to the designated ward for continuation of care.

02

Conditions studied

  • Anesthesia
  • Supraglottic Airway Efficiency
  • Paediatric Airway Management
03

In context

Lead sponsor

National University of Malaysia is the lead sponsor of 124 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are scheduled for a surgery under general anaesthesia where supraglottic airway is deemed appropriate.
  • Age up to 18 years old
  • Body weight of 10 kg and above

Exclusion criteria

Exclusion criteria

  • Presence of risk of gastric regurgitation or aspiration
  • Recent upper respiratory tract infection within 2 weeks
  • Uncontrolled respiratory co-morbidity such as bronchial asthma, chronic lung disease, restrictive lung disease
  • Presence of congenital airway abnormalities
  • Patient or next of kins refusal in participating this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Usage of SafeLM™ as the airway device

    SafeLM™ will be the airway device used for ventilation throughout the general anaesthesia period

    Device: SafeLM™ as the airway management device during general anaesthesia

Interventions

  • DeviceSafeLM™ as the airway management device during general anaesthesia

    Appropriate size of SafeLM™ is selected for participants as manufacturer recommendation. Size 2 is for participants with body weight of 10-20 kg, recommended cuff volume to be inflated is 10 to 15 ml. Size 2.5 is for participants with body weight of 20-30 kg, recommended cuff volume to be inflated is 14 to 21 ml. Size 3 is for participants with body weight of 30-50 kg, recommended cuff volume to be inflated is 20 to 30 ml. Size 4 is for participants with body weight of 50-70 kg, recommended cuff volume to be inflated is 30 to 45 ml Size 5 is for participants with body weight of 70-100 kg, recommended cuff volume to be inflated is 40 to 60 ml. Under general anaesthesia, the device is held by the anaesthesiologist at the distal end while advancing the laryngeal mask by sliding down the palatopharyngeal curve along the midline in the mouth until the end of the mask reach the hypopharynx cavity and resistance is met, under direct real-time visualisation.

06

What researchers measure

Primary outcomes

  1. Success rate of device placement in percentage

    Percentage of patient experiencing successful insertion of SafeLM™ The criteria of successful insertion: (i) good chest rise during positive pressure ventilation (ii) no significant air leakage (no audible leak on ausculatation, and the ventilator bellow not collapsing (iii) two or more continuous capnography waveforms (iv) able to achieve a minimum expiratory tidal volume of 6ml/kg Percetage calculation: number of participants fulfillling successful insertion criteria within 3 insertion attempts divided by total number of participants, multiplied by 100 percents

    Time frame: Perioperative

  2. Oropharyngeal leak pressure (OPLP) in cmH2O

    Oropharyngeal leak pressure (OPLP) is measured and recorded by dialling the fresh gas flow rate to 3 L/min and putting the adjusting pressure limiting (APL) valve at 40 cmH2O, in manual ventilation mode. The equilibrium pressure that the pressure gauze pointer settles down at is the OPLP. The measurement is done after successful device placement confirmation, once OPLP value is obtained, positive pressure ventilation of spontaneous ventilation will resume.

    Time frame: From the time of successful device placement confirmation to the time of determination of OPLP before commencement of surgery

  3. Glottic exposure grades

    SaCoVLM™ Glottic exposure grades visualised on the videoscope are recorded for each patient Grade 1: Visualization of the lateral part of the right aryepiglottic fold and part of the laryngeal inlet, and the ventilation was good Grade 2: Visualization of the bilateral aryepiglottic fold and part of laryngeal inlet, and the ventilation was good Grade 3: Visualization of all laryngeal inlet and posterior glottis Grade 4: Visualization of the whole glottis

    Time frame: At the time of completion of device placement procedure, when the distal end of the cuff reaches the hypopharyngeal cavity, resistance is met, and the cuff is inflated with appropriate volume of air as per manufacturer recommendation.

Secondary outcomes

  1. Insertion time in seconds (s)

    Time taken for device insertion. The duration in between the moment when the anaesthetist starts holding the SafeLM™ device, until the appearance of 2 complete continuous capnography waveform on the monitor is measured using stopwatch.

    Time frame: Periprocedural

  2. The ease of SafeLM™ insertion

    The anaesthetist will rate the ease of SafeLM™ insertion using Likert scale of 1 to 5 (1-Very easy, 2- Easy, 3-Somewhat easy, 4-Difficult, 5-Very difficult). Rating is done at the end of general anesthesia service in the operating theatre.

    Time frame: Perioperative

  3. Anaesthetists' overall satisfactory score

    The anaesthetists' overall satisfactory score will be rated using a scale of 1 to 5 (1-Very dissatisfied, 2-Dissatisfied, 3-Neutral, 4-Satisfied, 5-Very satisfied) Rating is done at the end of general anesthesia service in the operating theatre.

    Time frame: Perioperative

  4. Rate of intraoperative laryngospasm

    Presence of intra-operative laryngospasm event

    Time frame: Intraoperative

  5. Rate of intraoperative bronchospasm

    Presence of intra-operative bronchospasm event

    Time frame: Intraoperative

  6. Rate of intraoperative desaturation event

    Presence of desaturation event with pulse oximeter value of 90 percent and below

    Time frame: Intraoperative

  7. Rate of intraoperative gastric aspiration event

    Presence of intra-operative gastric aspiration event

    Time frame: Intraoperative

  8. Rate of post-extubation gastric aspiration event

    Presence of post-extubation gastric aspiration event from the time of extubation to the time of transfer out from Post anaesthesia care unit (PACU)

    Time frame: Perioperative

  9. Rate of post-extubation sore throat event

    Presence of post-extubation sore throat event from the time of extubation to the time of transfer out from Post anaesthesia care unit (PACU)

    Time frame: Perioperative

  10. Rate of post-extubation finding of blood stain

    Presence of blood stain on the SafeLM™ or oral cavity upon examination during extubation from the time of extubation to the time of transfer out from Post anaesthesia care unit (PACU)

    Time frame: Perioperative

  11. Rate of post-extubation laryngospasm

    Presence of post-extubation laryngospasm event from the time of extubation to the time of transfer out from Post anaesthesia care unit (PACU)

    Time frame: Perioperative

  12. Rate of post-extubation bronchospasm

    Presence of post-extubation bronchospasm event from the time of extubation to the time of transfer out from Post anaesthesia care unit (PACU)

    Time frame: Perioperative

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion May 2026 → Nov 2026 and completion May 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Dec 5, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Nov 30, 2026was May 2026
CompletionEst.
Dec 30, 2026was May 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Universiti Kebangsaan Malaysia · Cheras, Malaysiano status→Recruiting
  • University of Malaya · Kuala Lumpur, Malaysiano status→Recruiting
Nov 17, 2026
Primary completion
May 30, 2026→Nov 30, 2026
Nov 17, 2026
Study completion
May 30, 2026→Dec 30, 2026
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Universiti Kebangsaan Malaysia · Cheras, Malaysiano status→Recruiting
    • University of Malaya · Kuala Lumpur, Malaysiano status→Recruiting
    Primary completion May 30, 2026→Nov 30, 2026
    Study completion May 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07266389
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 2, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Rufinah Teo
Contact
rufinah@hctm.ukm.edu.my
+603-9145 5555

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion